

CLERK US DISTRICT COURT
NORTHERN DIST. OF TX
FILED

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF TEXAS
DALLAS DIVISION

2016 FEB 12 PM 1:53

DEPUTY CLERK

BLEPHEX, LLC

ORIGINAL

Plaintiff,

Civil Action No.

vs.

3-16CV-0410B

PAIN POINT MEDICAL SYSTEMS, INC.
d/b/a MIBO MEDICAL GROUP, INC.

Defendant.

COMPLAINT AND DEMAND FOR JURY TRIAL

Plaintiff Blephex, LLC ("Plaintiff" or "Blephex") hereby complains and alleges against Defendant Pain Point Medical Systems, Inc., doing business as MiBo Medical Group ("Defendant" or "MiBo") as follows:

NATURE OF THE ACTION

1. This is an action for active inducement of patent infringement and arises under the Patent Laws of the United States, codified in Title 35 of the United States Code.
2. On information and belief, MiBo has actively induced, and continues to actively induce, others to infringe Blephex's United States Patent No. 9,039,718 ("the '718 Patent" or "the Asserted Patent") in violation of 35 U.S.C. § 271(b).

THE PARTIES

3. Blephex is organized and existing under the laws of the State of Florida, and having its principal place of business at 3677 23rd Ave. South B103, Lake Worth, Florida 33461.

4. Upon information and belief, Pain Point Medical Systems, Inc., doing business as MiBo Medical Group, Inc. is a corporation organized and existing under the laws of the State of Texas and may be served with process through its registered agent, Glinda Whitehurst, at its principal place of business, 8204 Elmbrook Drive, Suite 200, Dallas, Texas 75247.

JURISDICTION AND VENUE

5. This Court has subject matter jurisdiction under 28 U.S.C. § 1331 and 28 U.S.C. § 1338(a).

6. This Court has personal jurisdiction over MiBo because, on information and belief: (i) as a corporation organized under the laws of the State of Texas with its principal place of business in Dallas, Texas, MiBo resides in the forum state, and specifically, within this judicial district; and (ii) MiBo has committed acts that constitute active inducement of patent infringement within the State of Texas, and specifically, within this judicial district.

7. Venue is proper in this judicial district based on 28 U.S.C. §§ 1391(b)(1), 1391(b)(2), and 28 U.S.C. § 1400(b).

FACTUAL BACKGROUND

8. Eye disorders relating to the eyelid margin are particularly common pathological conditions, especially among the elderly. Examples of such disorders include blepharitis, meibomitis, and dry eye syndrome. Dry Eye/Blepharitis Syndrome (“DEBS”) is a chronic, inflammatory disease of the eyelids caused by the presence of an overgrowth of normal bacteria along the lid and the base of the eyelashes. This overgrowth of bacteria produces a “biofilm” that builds up over the years and allows the bacteria to greatly increase in density. Once the bacteria reach a certain density, genes activate to allow the bacteria to produce toxins that penetrate the eyelid tissue causing low-grade chronic inflammation which adversely affects the quality and

quantity of tears being produced. Because eyelids are difficult to clean, this overgrowth of bacteria, biofilm, and toxins can worsen over time and eventually cause significant damage to the eyelid and tear glands.

9. Despite advances in ophthalmology and other medical treatments in general, the recommended treatments for disorders such as DEBS has remained essentially unchanged for decades. Historically, treatment begins and ends with the patient, who first begins to notice symptoms including eyelid redness, flaking of skin on the eyelids, crusting and/or cysts at the eyelid margins, and a gritty sensation of the eye culminating in irritation, burning, and reduced vision. Patients are generally prescribed a hygienic home treatment procedure involving antibiotics and/or topical steroid application. The goal of the home treatment procedure is to remove debris from the eyelid margin, which is critical to healing the eye and preventing reoccurrence of the disorder. To that end, the patient may also be required to attempt to remove debris from the eyelid using a cotton swab, a fingertip, or a scrub pad placed over the fingertip. Unfortunately for many patients, such hygienic home treatment generally achieves limited success due to the practical difficulties of cleaning one's own eye with an imprecise instrument such as a fingertip or cotton swab.

10. Through the efforts of Dr. James M. Rynerson, MD, Plaintiff Blephex LLC has developed a unique treatment for disorders such as DEBS, which involves a protocol that uses an electromechanical device to move a swab in contact with the eyelid margin to remove debris, encourage healing, and prevent reoccurrence of disorders involving the eyelid. More specifically, the BlephEx[®] device is comprised of a hand piece that very precisely and carefully, spins a medical grade micro-sponge along the edge of the eyelids and lashes to remove debris and to exfoliate the eyelid. Dr. Rynerson's treatment protocol has revolutionized the treatment of eye

disorders such as DEBS, and his innovations in the field have been recognized by the United States Patent and Trademark Office (“USPTO”).

11. On May 26, 2015, the USPTO duly and legally issued the ’718 Patent, entitled “Method and Device for Treating an Ocular Disorder,” to Dr. Rynerson. A copy of the ’718 Patent is attached to this complaint as Exhibit A.

12. Blephex is, and has at all times relevant to this complaint been, the owner by assignment of all right, title, and interest in the ’718 Patent.

13. The ’718 Patent discloses “[a] method and apparatus for treating ocular disorders such as blepharitis, meibomitis, and dry eye syndrome.” ’718 Pat, Abst. “The method includes using an electromechanical device to move a swab relative to the eye to create cyclical movement that impacts debris present at the eyelid margin and effectively removes the debris from the eye to encourage healing and prevent further digression of the health of the eye.” *Id.*

14. The ’718 Patent contains 17 claims, with Claims 1 and 17 being the only independent claims.

15. Claim 1 recites:

A method of treating an eye for an ocular disorder with a swab operably connected to an electromechanical device, wherein the eye has an eyelid margin and includes a removable debris, the method comprising:

effecting movement of the swab relative to the electromechanical device, the swab having at least a portion thereof configured to access an inner edge portion the eyelid margin;

while the swab is being moved by the electromechanical device, contacting a portion of the eye between the eyelashes and the inner edge of the eyelid margin that includes the removable debris with the swab thereby impacting the debris with the swab to remove debris from the eye.

’718 Pat., col. 7, ll. 30-43.

16. Claims 2-16 of the '718 Patent depend either directly or indirectly from Claim 1, and recite method steps to be followed in addition to those recited in Claim 1.

17. Claim 17 recites:

A method of treating an eye for an ocular disorder with a swab operably connected to an electromechanical device, wherein the eye has an eyelid margin and includes a removable debris, the method comprising;
effecting movement of the swab relative to the electromechanical device;
while the swab is being moved by the electromechanical device, contacting at least an inner edge portion of the eyelid margin that includes the removable debris with the swab thereby impacting the debris with the swab to remove debris from the eye.

'718 Patent, col. 8, ll. 47-57.

18. Blephex manufactures and sells a device, under the trademark BlephEx[®], that is used to practice the methods of treating eye disorders claimed in the '718 Patent.

19. Blephex sold its first BlephEx[®] device on July 3, 2013

20. The packaging of the BlephEx[®] device is marked with '718 Patent number and has been since at least June 12, 2015. Such marking constitutes constructive notice of Blephex's patent rights under 35 U.S.C. § 287.

21. The filing of this lawsuit provides actual notice of Blephex's rights in the '718 Patent, under 35 U.S.C. § 287.

22. On information and belief, MiBo has been aware of the BlephEx[®] device since at least September 20, 2015, when a MiBo representative named Dr. James Lewis gave a presentation at the Ocular Surface Disease Symposium at Salus University in Elkins Park, Pennsylvania. During that presentation, Dr. Lewis displayed and discussed a BlephEx[®] device.

Selected pages of the presentation referenced in this paragraph are attached to this complaint as Exhibit B.

23. Because the packaging of the BlephEx[®] device had been marked with the '718 Patent number since at least June 12, 2015, MiBo can be said to have known, or should have known, of the '718 Patent and Blephex's rights in the '718 Patent at least as of the date of the presentation given at the Ocular Surface Disease Symposium at Salus University in Elkins Park, Pennsylvania.

24. On or about November 23, 2015, Blephex became aware that Defendant MiBo was manufacturing and offering to sell a device known as the LidPro[®].

25. On information and belief, the LidPro[®] device contains a swab, as that element is defined by the '718 Patent, that is operably connected to an electromechanical device and at least a portion of the swab is configured to access an inner edge portion of an eyelid margin. When in use, the swab of the LidPro[®] device is moved by the electromechanical device to contact a portion of the eye between the eyelashes and the inner edge of the eyelid margin or, at least, an inner edge portion of the eyelid margin. When the swab of the LidPro[®] device is moved in this manner, it impacts and removes debris from the eye.

26. According to public statements made by MiBo, the LidPro[®] device is used, and has been used, to treat patients with eye disorders such as blepharitis. Specifically, a December 2, 2015 Facebook post by MiBo states:

Did you know that Mibo Medical Produces two innovative products for the treatment of Meibomian Gland Dysfunction?

The first is the Mibo Thermoflo a revolutionary heat treatment that is safe, effective, and has no consumables.

The second is the Lid Pro. The Lid pro is shown in the pictures below being done on a patient with severe anterior and posterior blepharitis. The patient was treated with the Lid Pro in office with great success and then had a Mibo treatment on

both eyes. Prior to this the patient was unable to watch his favorite TV shows without severe pain and redness. Now the patient has all day comfort and best of all – clear vision.

If you have questions about the Mibo Thermoflo of [sic: or] Lid Pro for your office or if you are a patient suffering with dry eye disease or Meibomian gland Dysfunction contact us today through the message function on our site or through our website.

The Facebook post referenced in this paragraph is attached to this complaint at Exhibit C.

27. Moreover, according to MiBo representatives, the LidPro[®] works to remove debris from the eyelid margin to treat eye disorders such as DEBS (or blepharitis) in the same way as the BlephEx[®] device does.

28. Furthermore, according to public statements made by MiBo representatives, MiBo had taken over 100 orders for its LidPro[®] device as of August 2015. Specifically, an August 27, 2015 Facebook post by MiBo representative Mike Whitehurst declares that:

It is unreal what the MiBo is doing. World wide sales. Next month we are introducing another device. It's called the LidPro. Already have taken 100 orders.

The Facebook post referenced in this paragraph is attached to this complaint as Exhibit D.

29. On information and belief, MiBo purports to be selling its LidPro[®] device for approximately \$700, which is a fraction of the cost of the BlephEx[®] device.

30. Further still, on information and belief, MiBo has provided exemplars of its LidPro[®] device to at least four eye care professionals. Those professionals include:

- (i) Glenn Corbin, 50 Berkshire Ct, Wyomissing, Pennsylvania 19610
- (ii) James Lewis, 8380 Old York Rd #110a, Elkins Park, PA 19027
- (iii) Walt Whitley, 241 Corporate Blvd # 210, Norfolk, Virginia 23502; and

(iv) Tom Kislam, 29 PA-611, Stroudsburg, Pennsylvania 18360

31. On information and belief, the four individuals named above have used, and are using, the LidPro[®] device in a manner that performs all the steps recited in, at least, Claims 1 and 17 of the '718 Patent. Accordingly, the four individuals named above are directly infringing at least Claims 1 and 17 of the '718 Patent by performing each and every step of the method claimed in Claims 1 and 17.

32. On information and belief, MiBo has instructed the four individuals named above to use, and continue using, the LidPro[®] device in a manner that performs all the steps recited in Claims 1 and 17 of the '718 Patent. As such, MiBo has actively induced the four individuals named above to infringe Claims 1 and 17 of the '718 Patent, because MiBo knew of the '718 Patent and still took active steps to encourage others to perform acts that MiBo knew, or should have known, constituted infringement of at least Claims 1 and 17 of the '718 Patent.

Count I – ACTIVE INDUCEMENT OF PATENT INFRINGEMENT
(Indirect Infringement of '718 Patent under 35 U.S.C. § 271(b))

33. The allegations of the preceding paragraphs are incorporated by reference as though fully set forth herein.

34. 35 U.S.C. § 271(a) provides that “[w]hoever without authority makes, uses, offers to sell, or sells any patented invention, within the United States or imports into the United States any patented invention during the term of the patent therefore, infringes the patent.”

35. 35 U.S.C. § 271(b) provides that “[w]hoever actively induces infringement of a patent shall be liable as an infringer.”

36. MiBo has actively induced the four individuals named above to directly infringe the claims of the '718 Patent, including, but not limited to, Claims 1 and 17.

37. MiBo knew, or should have known, of the '718 Patent since at least as early as September 20, 2015, as demonstrated by the presentation materials attached as Exhibit B.

38. MiBo provided the LidPro[®] device to the four individuals named above.

39. MiBo encouraged and instructed the four individuals named above to use the LidPro[®] device in a manner that performs each and every step of the method claimed in the '718 Patent, specifically, but not limited to, the method recited in Claims 1 and 17.

40. MiBo encouraged and instructed the four individuals named above to use the LidPro[®] device in a manner that performs each and every step of the method claimed in the '718 Patent with the knowledge that doing so would induce acts that constitute patent infringement.

41. On information and belief, MiBo's active inducement of infringement has been willful.

42. As a result of MiBo's wrongful conduct, Blephex has suffered, and will continue to suffer, substantial irreparable harm, including, but not limited to, lost market share and price erosion, for which it has no adequate remedy at law. Accordingly, Blephex is entitled to preliminary and thereafter permanent injunctive relief as set forth below. Further, Blephex has suffered, and will continue to suffer, damages in an amount to be determined at trial, due to MiBo's infringing conduct.

PRAYER FOR RELIEF

WHEREFORE, Blephex prays that the Court grant Blephex the following relief against MiBo:

A. That judgment be entered against MiBo, that MiBo has induced others to infringe the '718 Patent;

B. That MiBo, its agents, sales representatives, servants and employees, associates,

attorneys, parents, successors and assigns, and any and all persons or entities acting at, through, under or in active concert or participation with any or all of them, be preliminarily and permanently enjoined and restrained from further infringement, or active inducement of infringement, of the '718 Patent;

C. That judgment be entered requiring MiBo to pay to Blephex damages adequate to compensate Blephex for harm caused by MiBo's acts of active inducement of infringement, under 35 U.S.C. § 284;

D. That judgment be entered trebling such damages owed by MiBo due to its willful infringement of the '718 Patent, under 35 U.S.C. § 284;

E. That this case be declared exceptional under 35 U.S.C. § 285, and that Blephex be awarded its reasonable attorney fees;

F. That Blephex be awarded its costs and interest on all damages; and

G. That Blephex be awarded such other and further relief as the Court deems just and proper.


JURY DEMAND

Blephex hereby demands trial by jury of all issues raised that are triable by jury.

Respectfully submitted,

**SHACKELFORD, BOWEN, McKINLEY
& NORTON, LLP**

Dated: February 12, 2016



Derek Rollins
State Bar No. 24029803
(drollins@shackelfordlaw.net)
Gerald Conley
State Bar No. 04664200
(gconley@shackelfordlaw.net)
9201 N. Central Expressway
Fourth Floor
Dallas, Texas 75231
(214) 780-1400 – Telephone
(214) 780-1401 – Facsimile

ATTORNEYS FOR PLAINTIFF, BLEPHEX, LLC

Of Counsel:
Timothy D. Ardizzone, Ph.D., Esq.
tardizzone@whe-law.com
Paul J. Linden, Esq.
plinden@whe-law.com
WOOD HERRON & EVANS, LLP
441 Vine Street, 2700 Carew Tower
Cincinnati, Ohio 45202
Telephone: 513-241-2324
Facsimile: 513-241-6234

EXHIBIT A



US009039718B2

(12) **United States Patent**
Rynerson

(10) **Patent No.:** **US 9,039,718 B2**
(45) **Date of Patent:** **May 26, 2015**

(54) **METHOD AND DEVICE FOR TREATING AN OCULAR DISORDER**

2007/0231353 A1 10/2007 Gilbard et al.
2010/0256552 A1* 10/2010 Korb et al. 604/20
2014/0221908 A1* 8/2014 Sonsino et al. 604/28

(75) Inventor: **James M. Rynerson**, Alvaton, KY (US)

FOREIGN PATENT DOCUMENTS

(73) Assignee: **Blephex, LLC**, Lakeworth, FL (US)

CN	201692153 U	1/2011
JP	10108801 A	4/1998
WO	9633676 A1	10/1996
WO	2009066077 A1	5/2009
WO	2012092320 A2	7/2012
WO	2012092320 A3	7/2012

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 311 days.

OTHER PUBLICATIONS

(21) Appl. No.: **13/556,729**

(22) Filed: **Jul. 24, 2012**

(65) **Prior Publication Data**

US 2014/0031845 A1 Jan. 30, 2014

International Searching Authority, International Search Report and Written Opinion, International Application No. PCT/US2013/051850, mailed Oct. 14, 2013, 11 pp.
The Alger Company, Inc. "AlgerBrush II," available at <http://www.algercompany.com/download/ab_web/Algerbrush3_8.pdf>, accessed on Mar. 30, 2012, 1 page.

(Continued)

(51) Int. Cl.

A61F 9/007 (2006.01)

(52) U.S. Cl.

CPC **A61F 9/00709** (2013.01)

(58) **Field of Classification Search**

CPC **A61F 9/00; A61F 9/00709**
USPC 606/107, 162; 15/97.1; 128/898;
604/298-316; 601/72, 80, 139, 141,
601/142; 132/73.6, 75.8, 218

See application file for complete search history.

Primary Examiner — Todd Manahan

Assistant Examiner — Casey B Lewis

(74) Attorney, Agent, or Firm — Wood, Herron & Evans, LLP

(57)

ABSTRACT


A method and apparatus for treating ocular disorders such as blepharitis, meibomitis, and dry eye syndrome. The method includes using an electromechanical device to move a swab relative to the eye to create cyclical movement that impacts debris present at the eyelid margin and effectively removes the debris from the eye to encourage healing and prevent further digression of the health of the eye. The apparatus is an electromechanical device that includes a mechanical drive unit operatively connected to a swab to create a precise relative movement of the swab to the eye to remove debris present therein.

17 Claims, 2 Drawing Sheets

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,778,457 A	10/1988	York	
4,838,851 A	6/1989	Shabo	
4,955,896 A	9/1990	Freeman	
5,176,694 A *	1/1993	Price	606/162
2006/0116355 A1	6/2006	Van Breen	
2007/0016255 A1 *	1/2007	Korb et al.	607/1
2007/0060988 A1 *	3/2007	Grenon et al.	607/96



US 9,039,718 B2

Page 2

(56)

References Cited

OTHER PUBLICATIONS

1FORTHMONEY, et al. "Blepharitis," available at <<http://en.wikipedia.org/w/index.php?oldid=474399644>>, accessed on Mar. 12, 2012, 6 pp.

The Alger Co., Inc. [online retrieved on Dec. 22, 2014]. Retrieved from the internet at <<http://www.algercompany.com/brush/pdf-file/>>, click on "Operating/Sterilization Procedures" then click on Algerbrush II Operating Instruction Rev. 32012 to retrieve pdf submitted herewith as "Algerbrush-II-Operating_instruct. 2012".

The Alger Co., Inc. [online retrieved on Dec. 22, 2014]. Retrieved from the internet at <<http://www.algrecompany.com/brush/2013/01/>

02/the-algerbrush-ii-2/> Screen capture of page submitted herewith as "Algerbrush II Product Page."

Rhein Medical, Inc. [online retrieved on Jan. 8, 2015]. Retrieved from the internet at <<http://www.rheinmedical.com/products-page/algerbrushes/08-13154-algerbrush-ii-chuck-2-5mm-round-fine-gruit-diamond-ball/>> Screen capture of page submitted herewith as Algerbrush II chuck and round burr.

Ocusoft [online retrieved on Jan. 8, 2015]. Retrieved from the internet at <<http://www.ocusoft.com/Foreign-body-Removal-AKGERBRUSH-II-CHUCK-P4666.aspx>> Screen capture of page submitted herewith as Algerbrush II Chuck with bilobal fitting.



* cited by examiner

U.S. Patent

May 26, 2015

Sheet 1 of 2

US 9,039,718 B2



U.S. Patent

May 26, 2015

Sheet 2 of 2

US 9,039,718 B2




FIG. 2B

US 9,039,718 B2

1

METHOD AND DEVICE FOR TREATING AN OCULAR DISORDER

TECHNICAL FIELD

The present invention relates generally to a method and apparatus for treating an ocular disorder, and more particularly, to treating eyelid margin disease.

BACKGROUND

Ocular disorders such as those relating to eyelid margin disease are particularly common pathological conditions of the ocular adnexa. By way of example, these disorders include blepharitis, meibomitis, and dry eye syndrome. Despite advances in ophthalmology and medical treatments in general, the recommended treatments for these exemplary common ocular disorders has remained essentially unchanged for decades.

Historically, treatment of eyelid margin disease begins and ends with the patient. The patient first begins to notice symptoms including eyelid redness, flaking of skin on the eyelids, crusting and/or cysts at the eyelid margins, and a gritty sensation of the eye culminating in irritation, burning, and reduced vision. Should these symptoms remain unchanged or worsen, the patient routinely seeks the advice of an eye specialist, such as an ophthalmologist. After carefully considering the patients' medical history and investigating various possible causes, the specialist may prescribe a hygienic home treatment procedure for the patient to perform regularly in conjunction with antibiotics and/or topical steroids until the disease subsides.

The goal of the hygienic home treatment procedure is to remove debris, oil, and scurf that have collected along the eyelid margin during progression of the disorder. Removal of this debris is critical to both healing the eye and preventing a resurgence of the disorder. Without proper, regular removal of accumulated debris, such ocular disorders regularly worsen despite periodic treatments.

Hygienic home treatment of such ocular disorders is generally a two-step process. First, the patient softens the debris and scurf by applying a warm compress, diluted baby shampoo, or a specialized liquid solution to the eyelid margin. This first step is intended to prepare the debris for removal while preventing further irritation to the eye. Second, the patient attempts to remove the debris by physically scrubbing the eyelid margin, the base of the eyelashes, and the pores of the meibomian glands. This scrubbing is routinely attempted with either a generic cotton swab, a fingertip, or a scrub pad placed over the fingertip and applied against the eye. By cleaning debris and scurf free from the base of the eyelashes and unclogging the pores of the meibomian glands, the patient may improve the overall health of the eyelid margin; thereby reducing irritation, burning, and other symptoms related to the disorder.

Unfortunately for many patients, such hygienic home treatment is met with limited success due to the practical difficulties of cleaning one's own eye with an imprecise instrument such as a fingertip or cotton swab. For instance, many patients do not have the necessary dexterity to manipulate their fingertip or a cotton swab along the eyelid margin. Moreover, a shake, tremor, or poor near vision further complicate such self-treatment. Even for those capable of incorporating hygienic home treatment into their daily routine, many, if not most people, are wary of placing objects near their eyes to actively scrub along the eyelid margin. Given this anxiety, discomfort, and the inability to specifically target debris

2

deposits, patients routinely fail to totally cleanse the margin of the eyelid, the base of the eyelashes, and the meibomian glands. While the attempted treatment may temporarily abate the patient's symptoms, subtle continuation of the disease often persists; thus permitting a low-grade inflammation to develop and, ultimately lead to chronic dry eye syndrome. Further, this treatment is typically required to be performed for the rest of the patient's life; thereby, creating a substantial hurdle to regular and effective compliance during hygienic home treatment.

Evidence suggests that medical costs associated with dry eye syndrome, often induced by ocular diseases such as blepharitis, are currently over 68 billion dollars each year. Many of these expenses are needlessly incurred due to the patients' failure to perform regular and effective treatments resulting in increased doctor visits, medications, and artificial tears. These expenses create a significant financial burden for insurance carriers, especially Medicare, which provides primary medical coverage for many individuals particularly prone to dry eye disease, such as the elderly.

There is a need for a method and apparatus for use in treating ocular disorders, such eyelid margin diseases, that addresses present challenges and characteristics such as those discussed above.

SUMMARY

One exemplary embodiment of the method according to this invention comprises using a swab operably connected to an electromechanical device to treat an ocular disorder. The disorders to be treated via this method result in a build-up of a removable debris on the eye. The swab, which moves relative to the electromechanical device, contacts the portion of the eye that includes the removable debris. Thereby, the swab impacts the debris to remove the debris from the eye. Removing the debris further includes at least one of breaking the debris free of the eyelid margin, scrubbing the eyelid margin, exfoliating the eyelid margin, buffing the eyelid margin, or un-roofing the meibomian gland.

In one aspect, the swab is positioned near the eyeball along the eyelid margin to target the debris with the swab. The eyelid margin is accessed with the swab without the aid of a magnification device and without lifting the eyelid margin.

In another aspect, effecting movement of the swab relative to the electromechanical device includes at least one of rotating, vibrating, or reciprocating the swab. Furthermore, the movement of the swab may be set to a desirable speed.

Treating the eye for the ocular disorder may include repeating the effecting movement, the contacting the portion of the eye, and impacting the debris with the swab to remove the debris after periodic intervals until the ocular disorder is sufficiently remedied.

In another exemplary embodiment, a device for the removal of debris from the eye during the treatment of the ocular disorder comprises a swab having a tip portion and a base portion. The tip portion is of a sufficient size to access debris on the eye. The device also includes a rigid member and a mechanical drive unit. As such, the rigid member and the swab extend from an instrument. The rigid member has a distal end portion and a proximal end portion such that the distal end portion is affixed to the base portion of the swab and the proximal end portion is secured to the mechanical drive unit, which also includes a body. The mechanical drive unit operably moves the swab relative to the body facilitating removal of the debris from on the eye.

In one aspect, the swab is a generally egg-shaped sponge having an approximate length of two millimeters and a width

US 9,039,718 B2

3

of one millimeter. Affixed to the sponge, the rigid member is a plastic material that is formed onto the distal end portion of the rigid member.

In yet another aspect, the mechanical drive unit includes an electric motor, a chuck, and a control switch. The chuck projects from the body of the mechanical drive unit and is operably connected to the electric motor. Also, the control switch is operably coupled to the electric motor. With respect to the rigid member, the proximal end portion of the rigid member is removably secured to the chuck. In addition, the device is handheld and includes an electric power source operably coupled to the mechanical drive unit, the electric power source being a battery.

Various additional objectives, advantages, and features of the invention will be appreciated from a review of the following detailed description of the illustrative embodiments taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and, together with a general description of the invention given above, and the detailed description given below serve to explain the invention.

FIG. 1 is a perspective drawing of one embodiment of the device.

FIG. 2A is a drawing of the device of FIG. 1 treating a lower eyelid margin of an eye.

FIG. 2B is a drawing of the device of FIG. 1 treating an upper eyelid margin of an eye.

DETAILED DESCRIPTION

With reference to FIG. 1, an embodiment of the device 10 for treating an ocular disorder, particularly with respect to eyelid margin diseases, includes a mechanical drive unit 12 which operably moves a swab 14 to facilitate removal of debris from an eye 15 (see FIGS. 2A-2B). The swab 14 is connected to a rigid member 16 having both a distal end portion 18 and a proximal end portion 20. The swab 14 is affixed to the distal end portion 18 of the rigid member 16 to create an instrument 22, which may be secured to the mechanical drive unit 12. As shown in FIG. 1, the proximal end portion 20 is removably secured to the mechanical drive unit 12 in order to transmit motion from the mechanical drive unit 12, through the rigid member 16, and to the swab 14. It will be appreciated that any known method may be used to removably secure the instrument 22 to the mechanical drive unit 12. Moreover, it will also be appreciated that device 10 is not intended to be limited to the instrument 22 being removably secured to the mechanical drive unit 12. For instance, in another embodiment, the rigid member 16 may be either permanently secured or removably secured to either one of the swab 14 and/or the mechanical drive unit 12.

In one aspect of the instrument 22, the swab 14 includes a tip portion 24 and a base portion 26. While the swab 14 may be of a size sufficient to access debris on the eye 15 as shown in FIGS. 1-2B, at least the tip portion 24 is of a size sufficient to access debris on the eye 15. For instance, the swab 14 has an approximate length between 1.0-3.0 millimeters and an approximate width of between 0.5-1.5 millimeters. More particularly, the swab 14 has an approximate length of 2 millimeters and an approximate width of 1 millimeter. It will be appreciated that the swab 14 may be manufactured of any material suitable for contacting the eye 15 without harming the eye 15. However, as shown in the embodiment of FIG. 1,

4

the swab 14 is a sponge. As described herein, "sponge" broadly refers to any material that is soft, porous, and resilient. Particularly, the swab 14 is a medical grade sponge or a surgical grade sponge capable of removing debris from on the eye 15 without harming the eye 15. As shown in the exemplary embodiment of FIGS. 1-2B, the swab 14 is a methyl cellulose sponge. It will be appreciated; however, that similar materials capable of removing debris from on the eye 15 without harming the eye 15 are readily apparent and may also be used.

In another aspect of the instrument 22, the rigid member 16 is a plastic, cylindrical shaft including a central axis 27. The shaft extends along the central axis 27 between the mechanical drive unit 12 and the swab 14. The rigid member 16 is sufficiently rigid to effectively transmit motion from the mechanical drive unit 12 to the swab 14. As shown in FIG. 1, the swab 14 is permanently affixed to the distal end portion 18 by forming the base portion 26 to the rigid member 16 during manufacturing. However, it will be appreciated that any known method of affixing the swab 14 to the rigid member 16 may be used. In an exemplary embodiment, any material or shaft shape may be used so long as the rigid member 16 is rigid enough to transmit sufficient motion from the mechanical drive unit 12 to the swab 14 in order to remove debris from on the eye 15.

Furthermore, the mechanical drive unit 12 includes a body 28, an electric motor 30, a chuck 32, and a control switch 34. As such, the device 10 is electromechanical in nature. In an exemplary embodiment, the electric motor 30, the chuck 32, and the control switch 34 are integrated into the body 28 so that the electromechanical device 10 is configured to be handheld as shown in FIG. 1. However, the electromechanical device 10 is not intended to be limited to a handheld configuration, and it will be appreciated that other configurations of the device 10 are readily apparent.

According to the present embodiment, the electric motor 30 is positioned within the body 28. The chuck 32 is operably connected to the electric motor 30 at a forward end portion 36 of the body 28. The proximal end portion 20 of the rigid member 16 is removably secured to the chuck 32. As described herein, the chuck 32 is generally any element capable of removably securing the rigid member 16 to the mechanical drive unit 12. As such, the chuck 32 may be tightened or loosened to respectively secure or remove the instrument 22 to the chuck 32. Thereby, the operable connection of the electric motor 30 transmits a movement 38 through the chuck 32 to the instrument 22. The movement 38 is any motion relative to the mechanical drive unit 12 or, more particularly, to the body 28, that creates relative motion to the debris on the eye 15 such that upon contacting the debris with the swab 14, the debris is removed. As shown, the movement 38 may include, but is not limited to, a reciprocating movement 38a, a rotating movement 38b, or a vibrating movement 38c. The reciprocating movement 38a may be either along the central axis 27 of the rigid member 16 or orthogonal to the central axis 27 of the rigid member 16. In addition, the speed of the movement 28 of the swab 14 is any speed sufficient to remove debris from on the eye 15. It will be appreciated that the speed discussed herein collectively refers to both relative speed of the swab 14 and the frequency of the movement 38 of the swab 14. For instance, the frequency may range from sonic frequencies to ultrasonic frequencies. Furthermore, the speed of the swab 14 may be variable or otherwise selectable such that an operator of the device 10 may select a desirable speed or a forward or reverse direction via the control switch 34.

US 9,039,718 B2

5

Moreover, the control switch 34 is operably connected to the electric motor 30 and an electric power source 42 to power the device 10 on and off. In an exemplary embodiment, the electric power source 42 is a battery power source 42 contained within the body 28. The battery power source 42 may be either disposable or rechargeable. The electric power source 42 operably provides electrical power to the electric motor 30, which the operator controls via the control switch 34. It will be appreciated that any known control switch 34 or plurality of control switches 34 may be configured to power the device 10 on and off.

Furthermore, it will be appreciated that the device 10 may be manufactured from various materials suited to specific environments of use. For instance, operators within the professional clinic setting may desire a durable, reusable mechanical drive unit 12 and single-use instruments 22. Some examples of such a professional mechanical drive unit 12 is an Algerbrush I, an Algerbrush II, or similar medical device. However, operators within the home treatment setting may desire the device 10 to be generally disposable and single-use.

With respect to FIGS. 2A and 2B, the device 10 is used in a method for treating ocular disorders of the eye 15. For purposes of describing the environment in which this method occurs, FIGS. 2A and 2B generally show a portion of a face 50 having a nose 52, an eyebrow 54, and the eye 15. The eye 15 described herein generally includes, but is not limited to, an eyeball 56 including a cornea 58, an upper eyelid margin 60, a lower eyelid margin 62, and a plurality of eyelashes 64. In the exemplary embodiment, the device 10 is the swab 14 operably connected to the mechanical drive unit 12 thereby creating the electromechanical device 10 for use in removing debris deposited on at least one of either the upper eyelid margin 60 or the lower eyelid margin 62.

As shown in FIG. 1, the electromechanical device 10 is powered on and may be set to a desirable speed by the operator; thereby, the operator effects movement of the swab 14 relative to the electromechanical device 10. Such movement may include, but is not limited to, reciprocating the swab 14 as shown by arrows 38a, rotating the swab 14 as shown by arrow 38b, and/or vibrating the swab 14 as shown by lines 38c. The swab 14 is positioned near the eyeball 56 and along either one of the upper or lower eyelid margins 60, 62 for treatment. In the exemplary embodiment as shown in FIGS. 2A and 2B, the swab 14 moves with constant movement relative to the electromechanical device 10 while near the eyeball 56. Alternatively, it may be desirable to vary the movement of the swab 14 relative to the electromechanical device 10 such that the operator has greater control of treating the ocular disorder.

In an exemplary embodiment, the operator preferably targets the debris present on the eye 15 with the swab 14 of the electromechanical device 10. The debris may be targeted by visually inspecting the eye 15 with or without the aid of a magnification device. Once the debris is targeted, the swab 14 contacts the portion of the eye 15 that includes the debris. For purposes of treating the ocular disorder, the debris may be removably attached on either the upper and lower eyelid margins 60, 62 the plurality of eyelashes 64, or between the eyelashes 64 and the inner edge of the eyelid margins, 60, 62. Thereby, upon contacting the portion of the eye 15 with the debris, the swab 14 impacts the debris to remove the debris from the eye 15. Furthermore, a liquid solution configured to loosen the debris may be absorbed within the swab 14 to further aid in removing the debris from the eye 15 and/or minimizing irritation to the eye 15. It will be appreciated that

6

any liquid solution sufficiently capable of loosening the debris to further aid in removing the debris may be so used.

The electromechanical device 10 operably drives the swab 14 to break the debris free from either of the upper or lower eyelid margins 60, 62. Further treatment may be performed to enhance the effects of the debris removal by helping to improve healing and reducing further infection of the eye 15. Such treatment may include scrubbing, exfoliating, or buffing the eyelid margin or un-roofing a meibomian gland 66 with the swab 14.

In another aspect, the cornea 58 of the eye 15 is directed away from the position of the swab 14 to minimize contacting the swab 14 to the cornea 58 during treatment. As shown in FIG. 2A, while treating the lower eyelid margin 62, the eyeball 56 directs the cornea 58 upward, thereby bringing the cornea 58 closer to the upper eyelid margin 60 than the lower eyelid margin 62. However, as shown in FIG. 2B, while treating the upper eyelid margin 60, the eyeball 56 directs the cornea 58 downward, thereby being closer to the lower eyelid margin 62 than the upper eyelid margin 60.

As shown in FIG. 2A, accessing the portion of the eye 15 with the debris, such as the upper or lower eyelid margins 60, 62, may be accomplished without further moving or lifting other portions of the eye 15. However, as shown in FIG. 2B, if accessing the portion of the eye 15 with the debris is difficult, the operator may use a hand 68, or similar gripping device, to move or lift a portion of the eye 15, such as lifting the upper or lower eyelid margin 60, 62 from against the eyeball 56, to improve access to the debris. Such lifting may be particularly beneficial for improving access to the meibomian gland 66. It will be appreciated that, in order to improve access to the debris, any portion of the eye 15 may be moved or lifted regardless of which eyelid margins 60, 62 are being treated. FIGS. 2A and 2B are merely exemplary embodiments showing both non-assisted access and assisted access of the swab 14 to the eye 15 respectively.

Furthermore, the method of treating the ocular disorder may be repeated as directed by a physician or patient in order to sufficiently remedy the disorder. For instance, in the case of physician directed treatment, the physician may direct the patient to visit the physician in periodic intervals for treating the ocular disorder with the electromechanical device 10. More specifically, the physician directs the patient to visit the physician in periodic monthly or weekly intervals so that the physician may treat the patient. In the exemplary embodiment, periodic intervals are treatments with the electromechanical device 10 once every month. It will be appreciated that any periodic interval of repeating the method of treating the ocular disorder with the electromechanical device 10 may be so used.

Alternatively, in the case of home treatment by the patient, the patient may treat his or her own ocular disorder with the electromechanical device 10 in periodic intervals. However, according to the exemplary embodiment, the physician repeats the method of treating the ocular disorder in periodic intervals with the electromechanical device 10 and the patient also treats the ocular disorder in between physician treatments using traditional treatments. This method of treating the ocular disorder with the electromechanical device 10 in treatments occurring in periodic intervals achieves superior removal of the debris compared to traditional treatments, because the periodic intervals act as reminders to the patient. Thus, the patient is less likely to forget to treat the ocular disorders once symptoms begin to subside, which may result in a resurgence of the disorder. However, the traditional treatments, despite being less effective, may be performed regu-

US 9,039,718 B2

7

larly by the patient to further treat the ocular disorder in conjunction with physician treatments with the electromechanical device 10.

In any case, the physician or patient treats the ocular disorder until the ocular disorder is sufficiently healed and thereafter to prevent a recurrence of the disorder. It will be appreciated that sufficiently healed refers to the dissipation of inflammation and/or discomfort related to the debris within the eye 15 at which time the treatments by the physician may decrease in frequency, but may continue in periodic intervals during home treatment by the patient. In the event that the inflammation, discomfort, or debris worsens, the method of treating the ocular disorder may resume as the physician or patient desires. However, the treatment may be required in periodic intervals throughout the remainder of the patient's life.

While the present invention has been illustrated by the description of one or more embodiments thereof, and while the embodiments have been described in considerable detail, they are not intended to restrict or in any way limit the scope of the appended claims to such detail. Additional advantages and modifications will readily appear to those skilled in the art. The invention in its broader aspects is therefore not limited to the specific details, representative apparatus and method and illustrative examples shown and described. Accordingly, departures may be from such details without departing from the scope or spirit of the general inventive concept.

What is claimed is:

1. A method of treating an eye for an ocular disorder with a swab operably connected to an electromechanical device, wherein the eye has an eyelid margin and includes a removable debris, the method comprising;

effecting movement of the swab relative to the electromechanical device, the swab having at least a portion thereof configured to access an inner edge portion of the eyelid margin;

while the swab is being moved by the electromechanical device, contacting a portion of the eye between the eyelashes and the inner edge of the eyelid margin that includes the removable debris with the swab thereby impacting the debris with the swab to remove debris from the eye.

2. The method of claim 1 wherein the eye has a meibomian gland and removing debris further includes at least one of: scrubbing the eyelid margin; exfoliating the eyelid margin; buffing the eyelid margin; un-roofing the meibomian gland; or breaking the debris free of the eyelid margin.

3. The method of claim 1 wherein the eye has an eyeball and further includes accessing the eyelid margin for contacting the swab to the debris without lifting the eyelid margin from the eye.

4. The method of claim 1 wherein the eye has an eyeball and further includes:

positioning the swab near the eyeball along the eyelid margin; and
targeting the debris with the swab.

8

5. The method of claim 1 further including viewing the eye and the debris without the aid of a magnification device.

6. The method of claim 1 wherein the movement of the swab is at least one of rotating the swab, vibrating the swab, or reciprocating the swab.

7. The method of claim 1 wherein effecting movement of the swab further includes setting the movement of the swab to a desirable speed sufficient to remove the debris from the eye.

8. The method of claim 1 further including repeating the effecting movement, the contacting the portion of the eye, and impacting the debris with the swab to remove the debris process of claim 1 after periodic intervals until the ocular disorder is sufficiently remedied.

9. The method of claim 1 wherein the swab is connected to a rigid member having a proximal end portion, the method further comprising:

securing the proximal end portion of the rigid member to the electromechanical device; and

removing the proximal end portion of the rigid member from the electromechanical device.

10. The method of claim 9 further comprising:

removing the proximal end portion of the rigid member after a single use of the swab; and

repeating the securing and removing of another proximal end portion of another rigid member.

11. The method of claim 1 wherein the swab is a medical grade sponge for accessing the eyelid margin.

12. The method of claim 1 wherein the swab has a length and a width, the length being between 1.0 millimeter and 2.0 millimeters and the width being between 0.5 millimeters and 1.5 millimeters for accessing the inner edge portion of the eyelid margin.

13. The method of claim 1 wherein the swab is generally egg-shaped having an approximate length of 2 mm and an approximate width of 1 mm for accessing the inner edge portion of the eyelid margin.

14. The method of claim 1 further comprising:

accessing at least an inner edge portion of the eyelid margin with swab.

15. The method of claim 14 further comprising:

contacting the inner edge portion of the eyelid margin with the swab.

16. The method of claim 1 wherein the movement of the swab is rotating the swab.

17. A method of treating an eye for an ocular disorder with a swab operably connected to an electromechanical device, wherein the eye has an eyelid margin and includes a removable debris, the method comprising;

effecting movement of the swab relative to the electromechanical device;

while the swab is being moved by the electromechanical device, contacting at least an inner edge portion of the eyelid margin that includes the removable debris with the swab thereby impacting the debris with the swab to remove debris from the eye.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 9,039,718 B2
APPLICATION NO. : 13/556729
DATED : May 26, 2015
INVENTOR(S) : James M. Rynerson

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the specification,		
Column 1, line approximately 7, "disorder, and more"	should read	--disorder and, more--
Column 1, line approximately 28, "patients' medical"	should read	--patient's medical--
Column 2, lines approximately 14-15, "patients' failure"	should read	--patient's failure--
Column 2, line approximately 22, "such eyelid"	should read	--such as eyelid--
Column 4, line approximately 7, "appreciated; however"	should read	--appreciated, however--
Column 5, line approximately 61, "margins, 60, 62"	should read	--margins 60, 62--
Column 7, line approximately 26, "departures may be from"	should read	--departures may be made from--
In the claims,		
CLAIM 1, column 7, line 33, "method comprising;"	should read	--method comprising:--
CLAIM 12, column 8, line 30, "0.5 millimeters"	should read	--0.5 millimeter--
CLAIM 14, column 8, line 39, "with swab."	should read	--with the swab.--
CLAIM 17, column 8, line 48, "method comprising;"	should read	--method comprising:--

Signed and Sealed this
Twenty-second Day of December, 2015



Michelle K. Lee
Director of the United States Patent and Trademark Office

EXHIBIT B

Lewis, Devlin, Neal

OCULAR SURFACE DISEASE SYMPOSIUM

SEPTEMBER 20, 2015

Financial Disclaimer

❖ MiBoMedicalGroup: Equity Shareholder (Lewis)

OCULAR SURFACE DISEASE SYMPOSIUM

SUNDAY
SEPTEMBER 20, 2015
8 Hours — COPE Approval Pending



SALUS
UNIVERSITY
Pennsylvania College of Podiatric
Room 300 South
Elkins Park, PA 19027

12:35 PM

OCULAR SURFACE DISEASE

Latest Diagnostic Techniques

MARCUS DEWITT, OD, JAMES LEWIS, MD

and Brett Neal, OD

Diagnostics

❖ Clinical

❖ Imaging

❖ Quantitative Methods

Composition


❖ aqueous

❖ lipid


❖ debris

CONFIDENTIAL


[Redacted signature line]














EXHIBIT C

This is Google's cache of <https://www.facebook.com/MiboMyDryEye/posts/1522377854741442>. It is a snapshot of the page as it appeared on Dec 6, 2015 14:34:27 GMT.

The current page could have changed in the meantime. Learn more

Full version Text-only version View source

Tip: To quickly find your search term on this page, press **Ctrl+F** or **⌘-F** (Mac) and use the find bar.

facebook [Sign Up](#)

Email or Phone

Password

☐ Keep me logged in [Forgot your password?](#)



Mibo Thermoflo added 5 new photos.

December 2 at 3:13pm · 🌐


Did you know that Mibo Medical Produces two innovative products for the treatment of Meibomian Gland Dysfunction?

The first is the Mibo Thermoflo a revolutionary heat treatment that is safe, effective, and has no consumables.

The second is the Lid Pro. The Lid pro is shown in the pictures below being done on a patient with severe anterior and posterior blepharitis. The patient was treated with the Lid Pro in office with great success and then had a Mibo treatment on both eyes. Prior to this the patient was unable to watch his favorite TV shows without severe pain and redness. Now the patient has all day comfort and best of all --- clear vision.

If you have questions about the Mibo Thermoflo or Lid Pro for your office or if you are a patient suffering with dry eye disease or Meibomian Gland Dysfunction contact us today through the message function on our site or through our website.

<http://mibomedicalgroup.com/how-miboflo-works/>



👍 Like 💬 Comment

[English \(US\)](#) · [Privacy](#) · [Terms](#) · [Cookies](#) · [Advertising](#) · [Ad Choices](#) · [More](#) · Facebook © 2015

EXHIBIT D

File Edit View History Bookmarks Tools Help

lidpro mibo archive.org Trademark Dry Eyes Tr (4) mibo... x USPTO TSD aoc051

https://www.facebook.com/search/top/?q=mibo thermoflo lidpro lidpro mibo

mibo thermoflo lidpro

Top Latest People Photos Videos Pages Places Groups Apps

FAVORITES

- Messages 10
- Sale Groups
- Pokes 3
- New Groups 4
- Stay strong Zach~ sk... 6
- Prayer/Update Page f... 20+
- North Louisianians U... 20+
- STAY STRONG ZACH 20+
- Suggest Edits
- Photos


FACEBOOK

- News Feed
- Events 1 invite
- Groups
- Pages
- Games & Apps
- Lists

Public Posts

Mike Whitehurst
August 27, 2015 · Irving, TX ·

GG and I are going on a workcation on Tuesday. Barcelona Spain. Our partner Mike Lutz is also going. It's the big Euro eye expo. Have a booth for the MiBo. A lot of interest in the MiBo. We will be gone 10 days. Yes we have a house keeper. It is unreal what the MiBo is doing. World wide sales. Next month we are introducing another device. It's called the LidPro. Already have taken over 100 orders. MiBo Medical is one of the fastest growing companies I have ever been involved with. mibomedicalgroup.com We will post photos of our workcation. Hope you all follow our trip.



JS 44-TXND (Rev. 12/12)

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM)

I. (a) PLAINTIFFS
BLEPHEX, LLCDEFENDANTS
PAIN POINT MEDICAL SYSTEMS, INC. and PAIN POINT MEDICAL GROUP, INC.(b) County of Residence of First Listed Plaintiff Palm Beach County
(EXCEPT IN U.S. PLAINTIFF CASES)County of Residence of First Listed Defendant Dallas
(IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.

Attorneys (If Known)

(c) Attorneys (Firm Name, Address, and Telephone Number)
Derek Rollins/Gerald Conley
Shackelford, Bowen, McKinley & Norton, LLP, 9201 N. Central Expwy.,
Fourth Floor, Dallas TX 75231 (214) 780-1400

3-16CV-0410B

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- ☐ 1 U.S. Government Plaintiff
- ☒ 3 Federal Question
(U.S. Government Not a Party)
- ☐ 2 U.S. Government Defendant
- ☐ 4 Diversity
(Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- | | PTF | DEF | | PTF | DEF |
|---|----------------------------|----------------------------|---|----------------------------|----------------------------|
| Citizen of This State | <input type="checkbox"/> 1 | <input type="checkbox"/> 1 | Incorporated or Principal Place of Business In This State | <input type="checkbox"/> 4 | <input type="checkbox"/> 4 |
| Citizen of Another State | <input type="checkbox"/> 2 | <input type="checkbox"/> 2 | Incorporated and Principal Place of Business In Another State | <input type="checkbox"/> 5 | <input type="checkbox"/> 5 |
| Citizen or Subject of a Foreign Country | <input type="checkbox"/> 3 | <input type="checkbox"/> 3 | Foreign Nation | <input type="checkbox"/> 6 | <input type="checkbox"/> 6 |

IV. NATURE OF SUIT (Place an "X" in One Box Only)

CONTRACT	TORTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES	
<input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment <input type="checkbox"/> 151 Medicare Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excludes Veterans) <input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability <input type="checkbox"/> 196 Franchise	PERSONAL INJURY <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Federal Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input type="checkbox"/> 360 Other Personal Injury <input type="checkbox"/> 362 Personal Injury - Medical Malpractice	PERSONAL INJURY <input type="checkbox"/> 365 Personal Injury - Product Liability <input type="checkbox"/> 367 Health Care/Pharmaceutical Personal Injury Product Liability <input type="checkbox"/> 368 Asbestos Personal Injury Product Liability PERSONAL PROPERTY <input type="checkbox"/> 370 Other Fraud <input type="checkbox"/> 371 Truth in Lending <input type="checkbox"/> 380 Other Personal Property Damage <input type="checkbox"/> 385 Property Damage Product Liability	<input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881 <input type="checkbox"/> 690 Other LABOR <input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Management Relations <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 751 Family and Medical Leave Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Employee Retirement Income Security Act IMMIGRATION <input type="checkbox"/> 462 Naturalization Application <input type="checkbox"/> 465 Other Immigration Actions	<input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157 PROPERTY RIGHTS <input type="checkbox"/> 820 Copyrights <input checked="" type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark SOCIAL SECURITY <input type="checkbox"/> 861 HIA (1395ff) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIWC/DIWW (405(g)) <input type="checkbox"/> 864 SSID Title XVI <input type="checkbox"/> 865 RSI (405(g)) FEDERAL TAX SUITS <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS—Third Party 26 USC 7609	<input type="checkbox"/> 375 False Claims Act <input type="checkbox"/> 400 State Reapportionment <input type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations <input type="checkbox"/> 480 Consumer Credit <input type="checkbox"/> 490 Cable/Sat TV <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 890 Other Statutory Actions <input type="checkbox"/> 891 Agricultural Acts <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 895 Freedom of Information Act <input type="checkbox"/> 896 Arbitration <input type="checkbox"/> 899 Administrative Procedure Act/Review or Appeal of Agency Decision <input type="checkbox"/> 950 Constitutionality of State Statutes
REAL PROPERTY <input type="checkbox"/> 210 Land Condemnation <input type="checkbox"/> 220 Foreclosure <input type="checkbox"/> 230 Rent Lease & Ejectment <input type="checkbox"/> 240 Torts to Land <input type="checkbox"/> 245 Tort Product Liability <input type="checkbox"/> 290 All Other Real Property	CIVIL RIGHTS <input type="checkbox"/> 440 Other Civil Rights <input type="checkbox"/> 441 Voting <input type="checkbox"/> 442 Employment <input type="checkbox"/> 443 Housing/Accommodations <input type="checkbox"/> 445 Amer. w/Disabilities - Employment <input type="checkbox"/> 446 Amer. w/Disabilities - Other <input type="checkbox"/> 448 Education	PRISONER PETITIONS Habeas Corpus: <input type="checkbox"/> 463 Alien Detainee <input type="checkbox"/> 510 Motions to Vacate Sentence <input type="checkbox"/> 530 General <input type="checkbox"/> 535 Death Penalty Other: <input type="checkbox"/> 540 Mandamus & Other <input type="checkbox"/> 550 Civil Rights <input type="checkbox"/> 555 Prison Condition <input type="checkbox"/> 560 Civil Detainee - Conditions of Confinement			

V. ORIGIN (Place an "X" in One Box Only)

- ☒ 1 Original Proceeding
- ☐ 2 Removed from State Court
- ☐ 3 Remanded from Appellate Court
- ☐ 4 Reinstated or Reopened
- ☐ 5 Transferred from Another District (specify)
- ☐ 6 Multidistrict Litigation

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):
35 U.S.C. Section 271(b)Brief description of cause:
Patent infringement

VII. REQUESTED IN COMPLAINT:

☐ CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P.

DEMAND \$ _____

Preliminary Injunction/Damages

CHECK YES only if demanded in complaint:

JURY DEMAND: ☒ Yes ☐ No

VIII. RELATED PENDING OR CLOSED CASE(S)

IF ANY

(See instructions):

JUDGE N/A

DOCKET NUMBER N/A

DATE
02/12/2016

SIGNATURE OF ATTORNEY OF RECORD

FOR OFFICE USE ONLY

RECEIPT # _____ AMOUNT _____ APPLYING IFP _____ JUDGE _____ MAG. JUDGE _____